UA112863C2 - Імуногенна композиція для профілактики і/або лікування інфекції, яка викликана вірусом віл - Google Patents

Імуногенна композиція для профілактики і/або лікування інфекції, яка викликана вірусом віл Download PDF

Info

Publication number
UA112863C2
UA112863C2 UAA201311896A UAA201311896A UA112863C2 UA 112863 C2 UA112863 C2 UA 112863C2 UA A201311896 A UAA201311896 A UA A201311896A UA A201311896 A UAA201311896 A UA A201311896A UA 112863 C2 UA112863 C2 UA 112863C2
Authority
UA
Ukraine
Prior art keywords
peptide
hiv
cells
antibodies
formula
Prior art date
Application number
UAA201311896A
Other languages
English (en)
Ukrainian (uk)
Inventor
Патріс Дебр
Венсан В'єйар
Original Assignee
Інститут Насьональ Де Ла Сант Ет Де Ла Решерш Медікаль
Іннавірвакс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Інститут Насьональ Де Ла Сант Ет Де Ла Решерш Медікаль, Іннавірвакс filed Critical Інститут Насьональ Де Ла Сант Ет Де Ла Решерш Медікаль
Publication of UA112863C2 publication Critical patent/UA112863C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
UAA201311896A 2011-04-15 2012-04-13 Імуногенна композиція для профілактики і/або лікування інфекції, яка викликана вірусом віл UA112863C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11305451A EP2511295A1 (en) 2011-04-15 2011-04-15 Compositions for preventing and/or treating an infection by an HIV-1 virus
PCT/IB2012/051842 WO2012140620A1 (en) 2011-04-15 2012-04-13 Compositions for preventing and/or treating an infection by an hiv-1 virus

Publications (1)

Publication Number Publication Date
UA112863C2 true UA112863C2 (uk) 2016-11-10

Family

ID=44721142

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201311896A UA112863C2 (uk) 2011-04-15 2012-04-13 Імуногенна композиція для профілактики і/або лікування інфекції, яка викликана вірусом віл

Country Status (11)

Country Link
US (3) US9181299B2 (https=)
EP (2) EP2511295A1 (https=)
JP (1) JP6027094B2 (https=)
CN (1) CN103687875B (https=)
BR (1) BR112013026150B1 (https=)
CA (1) CA2831258C (https=)
ES (1) ES2912099T3 (https=)
RU (1) RU2603262C2 (https=)
UA (1) UA112863C2 (https=)
WO (1) WO2012140620A1 (https=)
ZA (1) ZA201307019B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016184962A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016184963A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
AU2017410525B2 (en) * 2017-04-18 2022-04-21 Institute Of Pathogen Biology, Chinese Academy Of Medical Sciences Potent HIV inhibiting lipopeptide, derivative thereof, pharmaceutical composition thereof and use thereof
EP4115900A1 (en) * 2021-07-05 2023-01-11 Diaccurate Novel antigens and vaccines

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
EP0378881B1 (en) 1989-01-17 1993-06-09 ENIRICERCHE S.p.A. Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
ES2275499T3 (es) 1999-03-19 2007-06-16 Glaxosmithkline Biologicals S.A. Vacuna contra streptococcus pneumoniae.
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US6399067B1 (en) * 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
AU2002251058A1 (en) * 2001-02-16 2002-09-04 Hybrigenics Protein-protein interactions in saccharomyces cerevisiae
FR2851165A1 (fr) * 2003-02-19 2004-08-20 Aventis Pasteur Antigene derivant de l'helice c de la proteine gp41
US8088976B2 (en) * 2005-02-24 2012-01-03 Monsanto Technology Llc Methods for genetic control of plant pest infestation and compositions thereof
US8961987B2 (en) * 2007-08-20 2015-02-24 New York University Immunogen comprising the HIV GP120 V3 loop in a conformation that induces broadly neutralizing antibodies
EA201170947A1 (ru) * 2009-01-28 2012-07-30 Басф Плант Сайенс Компани Гмбх Растения, имеющие улучшенные характеристики урожайности, и способ их получения
US8652459B2 (en) * 2009-02-06 2014-02-18 Mymetics Corporation Splitting GP41
US20120164670A1 (en) * 2009-06-23 2012-06-28 President And Fellows Of Harvard College Methods and kits for measuring enzyme activity

Also Published As

Publication number Publication date
EP2697259B1 (en) 2022-02-09
RU2603262C2 (ru) 2016-11-27
US20180057535A1 (en) 2018-03-01
US9802983B2 (en) 2017-10-31
US20140037666A1 (en) 2014-02-06
ZA201307019B (en) 2014-12-23
WO2012140620A1 (en) 2012-10-18
EP2697259A1 (en) 2014-02-19
CA2831258C (en) 2020-07-14
ES2912099T3 (es) 2022-05-24
BR112013026150A2 (pt) 2016-09-06
CN103687875B (zh) 2016-10-19
JP6027094B2 (ja) 2016-11-16
WO2012140620A8 (en) 2013-11-07
CN103687875A (zh) 2014-03-26
EP2511295A1 (en) 2012-10-17
JP2014512367A (ja) 2014-05-22
RU2013145467A (ru) 2015-05-20
US9181299B2 (en) 2015-11-10
US20160031943A1 (en) 2016-02-04
BR112013026150B1 (pt) 2022-08-09
CA2831258A1 (en) 2012-10-18
US10174080B2 (en) 2019-01-08

Similar Documents

Publication Publication Date Title
AP237A (en) Immunoreagents reactive with a conserved epitope of human immunodeficiency virus type 1 (HIV-1) gp120 and methods of use.
US12303477B2 (en) HIV treatment compositions and methods
RU2603732C2 (ru) Способ быстрого отбора вариантов gp-120 вич
US10174080B2 (en) Compositions for preventing and/or treating an infection by an HIV-1 virus
US8722861B2 (en) Monoclonal antibodies that bind to the V3 loop of HIV-1 gp120
Sullivan et al. Complement can neutralize HIV-1 plasma virus by a C5-independent mechanism
CN107074944B (zh) 藉由针对cd4之单克隆抗体介导竞争型hiv进入抑制之hiv感染的治疗和功能性治愈
Galéa et al. Rationale for a vaccine using cellular-derived epitope presented by HIV isolates
CN109627297A (zh) 来自寨卡病毒e蛋白的中和表位及其应用
AU651794B2 (en) Human monoclonal antibodies to human immunodeficiency virus
Xiao et al. Purified complexes of HIV-1 envelope glycoproteins with CD4 and CCR5 (CXCR4): production, characterization and immunogenicity
EP0787211A1 (en) Method for identifying protective antigens for eliciting neutralizing antibodies
Scheglovitova et al. Antibody to ICAM-1 mediates enhancement of HIV-1 infection of human endothelial cells
US20170128564A1 (en) POLYPEPTIDE DERIVED FROM gp41, A VACCINE COMPOSITION COMPRISING SAID POLYPEPTIDE, AND USES FOR TREATING AN INFECTION BY AN HIV VIRUS IN AN INDIVIDUAL
Reuben et al. B-cell activation and differentiation by HIV-1 antigens among volunteers vaccinated with VaxSyn HIV-1
JPH0475583A (ja) ハイブリドーマ系細胞とその細胞により産生されるモノクローナル抗体
Février et al. Two new human monoclonal antibodies against HIV type 1 glycoprotein 120: characterization and neutralizing activities against HIV type 1 strains
Fauci Cellular Pathogenesis
Zoltán Prohászka et al. Complement-Mediated Antibody-Dependent Enhancement of Viral Infections
MARSCHKE et al. Soluble CD4-PE40 Is Cytotoxic for a Transfected Mammalian Cell Line Stably Expressing the Envelope Protein of Human Immunodeficiency Virus (HIV-1), and Cytotoxicity Is Variably Inhibited by the Sera of HIV-l-Infected Patients
Gawron et al. Impact of IgA Constant Domain on HIV-1